J&J Chief Financial Officer Joe Wolk has said the Stelara biosimilar market was likely to unfurl similarly to that of ...

After 42 successful years, the controversial chain Hooters may be on the brink of bankruptcy, like several other chains in ...

CVS director Mike Mahoney, whose day job is CEO of Boston Scientific, bought 30,000 shares of the healthcare company.

Principal Securities Inc. grew its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 3.2% during the fourth ...

Despite a recent 45% rally, I maintain a 'Sell' view on CVS due to its underwhelming execution record and rising leverage ...

In the latest executive shakeup at CVS, the pharmacy giant has named a new president of its pharmacy benefit management ...

Argus raised the firm’s price target on CVS Health (CVS) to $77 from $68 and keeps a Buy rating on the shares. Despite an uneven performance ...

In a report released on February 14, Steven Silver from Argus Research maintained a Buy rating on CVS Health (CVS – Research Report). The ...

Earnings have fallen but are still strong enough to meet CVS Health's dividend commitment. Management expects adjusted ...

Shares in Asia were mostly up Tuesday, with Chinese technology stocks surging after Chinese President Xi Jinping met with ...

We recently compiled a list of the 10 Best Performing S&P 500 Stocks So Far in 2025. In this article, we are going to take a ...

New York Times Co.’s stock fell sharply on Wednesday as analysts questioned a sequential increase in the money the company spends to advertise its media properties. The New York Times NYT also ...